

---

**Education**

---

University	BS (Chemical Engineering), Cornell University, Ithaca, NY	1977
Graduate	MS (Bioengineering) University of Utah, Salt Lake City, UT	1979
Medical School	MD, University of Vermont, Burlington, VT	1983
Residency	Internal Medicine, University of Colorado HSC	1983-1986
Fellowship	Cardiology, University of Wisconsin Hospital	1986-1989

---

**Board Certification**

---

American Board of Internal Medicine	1986
American Board of Internal Medicine, Cardiovascular Disease	1989

---

**Honors**

---

Excellence in Teaching Award, fourth year medical students	May 1993
Outstanding Cardiology Faculty Award, cardiology fellows	1993-1994
Outstanding Faculty Teaching Award, Denver Health & Hospitals	2002
Elite Reviewer, Journal of the American College of Cardiology	2004

---

**Publications**

---

Peer-reviewed journal articles

1. **Havranek EP** and Dunbar DN. Exertional syncope caused by left main coronary artery spasm. *Am Heart J* 1992; 123:792-794.
2. **Havranek EP**, Bailey WN, and Adair OV. Left ventricular diastolic collapse in the absence of cardiac tamponade. *Echocardiography* 1993;10:1-4.
3. Read RA, Moore EE, Moore FA, **Havranek EP**, Veerakul G, Mestek M, Nademanee K. Intravascular ultrasound (IVUS) for the diagnosis of traumatic aortic disruption: a case report. *Surgery* 1993; 114:624-628.
4. **Havranek EP**. Management of the patient with myocardial infarction following hospital discharge. *Am Fam Phys* 1994; 49:1109-1119.
5. **Havranek EP**. The management of atrial fibrillation: new perspectives on a common problem. *Am Fam Phys* 1994; 959-968.
6. **Havranek EP**. Is cholesterol lowering an alternative to revascularization in some patients with coronary artery disease? *Arch Int Med* 1995; 155:670-675.
7. **Havranek EP**, Sherry PD. Left heart catheterization by direct puncture with two dimensional echocardiographic guidance. *Cath Cardiovasc Design* 1995; 35:358-361.
8. **Havranek EP**, Dwinnell B, Smith KS. Multiorgan failure after cardiac arrest in a 20 year-old man. *Circulation* 1995; 92:3139-3143.
9. Estacio R, Wolfel E, Reusch J, **Havranek E**, Regensteiner J, Johnson-Nagel N, Savage S, Schrier R. Effect of risk factors on exercise capacity in non-insulin dependent diabetes (NIDDM): role of hypertension, obesity, age, and ethnicity. *Diabetes* 1996; 45:79-85.
10. **Havranek EP**, Graham GW, Pan Z, Lowes B. Process and outcome of outpatient management of heart failure: a comparison of cardiologists and primary care providers. *Am J Managed Care* 1996; 2: 783-789.

11. **Havranek EP**, Nadamanee K, Grayburn PA, Eichhorn EJ. Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy. *J Am Coll Cardiol* 1996; 28: 1168-1174 .
12. **Havranek EP**, Stevens E, Parker K, Abrams F. Determinants of mortality in elderly patients with heart failure: the role of angiotensin converting enzyme inhibitors. *Arch Int Med* 1998;158:2024-2028.
13. **Havranek EP**. Primary prevention of CHD: Nine ways to reduce risk. *Am Fam Phys* 1999; 59: 1455-1463.
14. **Havranek EP**, Thomas I, Smith WB, Ponce G, Bilsker M, Munger M, Lyver S, Aarons D, Graves T, Wolf RA for the Irbesartan CHF Group. Dose-related beneficial long-term hemodynamic and clinical effects of irbesartan in heart failure. *J Am Coll Cardiol* 1999: 1174-1181.
15. Estacio RO, Jeffers BW, **Havranek EP**, Krick D, Samson O, Schrier RW. Deletion polymorphism of the angiotensin converting enzyme (ACE) gene is associated with an increase in left ventricular mass in males with NIDDM. *Am J Hypertension* 1999; 12: 637-42.
16. **Havranek EP**, Lowes BL, Abraham WT, McGovern K. Utilities are valid measures of health related quality of life in patients with heart failure. *J Cardiac Failure* 1999; 5: 85-91.
17. **Havranek EP**, Ware MG, Lowes BL. The prevalence of depression in patients with heart failure. *Am J Cardiol* 1999; 84: 348-350.
18. Krumholz HM, Baker DW, Ashton CM, Dunbar SB, Friesinger GC, **Havranek EP**, Hlatky MA, Konstam M, Ordin DL, Pina IL, Pitt B, Spertus JA. Evaluating quality of care for patients with heart failure. *Circulation* 2000; 101: e122-e140.
19. Quality of Care and Outcomes Research in CVD and Stroke Working Group. Measuring and improving quality of care: a report from the American Heart Association/American College of Cardiology First Scientific Forum on Healthcare Quality in Cardiovascular Disease and Stroke. *Circulation* 2000; 101: 1483-93.
20. Sauaia A, Ralston D, Schluter WW, Marciniak TA, **Havranek EP**, Dunn TR. Influencing care in acute myocardial infarction: a randomized trial comparing two types of intervention. *Am J Medical Quality* 2000; 15; 197-206.
21. **Havranek EP**, Lapuerta P, Simon TA, L'Italien G, Block AJ, Rouleau JL. A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. *J Cardiac Failure* 2001; 7: 153-7.
22. Krantz MJ , Woods JE, **Havranek EP**, Linas S. Simultaneous malignant hypertension and cardiac tamponade. *Am J Kidney Dis* 2002; 39(3): E17.
23. Masoudi FA, **Havranek EP**, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. *Heart Failure Reviews* 2002; 7: 9-16.
24. **Havranek EP**, Masoudi FA, Westfall K, Wolfe P, Ordin DL, Krumholz HM. The spectrum of heart failure in older adults: Results from the National Heart Failure project. *Am Heart J* 2002; 143: 412-7.

25. Gottlieb SS, Brater DC, Thomas I, **Havranek E**, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, and Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. *Circulation* 2002; 105: 1348-1353.
26. Masoudi FA, **Havranek EP**, Smith G, Fish R, Krumholz HM, Steiner JF, Ordin DL, Krumholz HM. Gender, age and heart failure with preserved left ventricular systolic function. *J Am Coll Cardiol* 2003; 41: 217-23.
27. **Havranek EP**, Masoudi FA, Rumsfeld JS, Steiner JF. A broader paradigm for understanding and treating heart failure. *J Cardiac Failure*; 2003; 9:147-152.
28. Lindenfeld J, Fiske KS, Stevens BR, Debuhr J, **Havranek EP**, Abrams FR. Age, but not sex, influences the measurement of ejection fraction in elderly patients hospitalized for heart failure. *J Cardiac Failure* 2003; 9: 100-106.
29. Rathore SS, Foody JM, Wang Y, Smith GL, Herrin J, Masoudi FA, Wolfe P, **Havranek EP**, Ordin DL, Krumholz HM. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. *JAMA* 2003; 289: 2517-2524.
30. **Havranek EP**, Esler A, Mehler PS, Estacio RO, Schrier RW. Differential effects of anti-hypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. *Am Heart J* 2003; 145: 993-8.
31. Masoudi FA, Wang, Y, Inzucchi SE, Setaro JF, **Havranek EP**, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. *JAMA* 2003; 290; 81-5.
32. Masoudi FA, **Havranek EP**, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. *Am Heart J* 2003; 146: 250-7.
33. **Havranek EP**, Krumholz HM, Dudley RA, Adams K, Gregory D, Lindenfeld JA, Massie B, Pina I, Restaino S, Rich MW, Konstam MA. Aligning quality and payment for heart failure care: defining the challenges. *J Cardiac Failure* 2003; 9: 251-4.
34. Rumsfeld JS, **Havranek EP**, Masoudi FM, Peterson ED, Jones P, Tooley JF, Krumholz HM, Spertus JA for the Cardiovascular Outcomes Research Consortium (CORC). Depressive symptoms are the strongest predictor of short-term declines in health status in patients with heart failure. *J Am Coll Cardiol* 2003; 42: 1811-7.
35. Curtis JP, Wang Y, Portnay EL, Masoudi FA, **Havranek EP**, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: a retrospective cohort analysis. *BMJ* 2003; 327: 1322-3.
36. Foody JM, Rathore SS, Wang Y, Herrin J, Masoudi FM, **Havranek EP**, Radford MJ, Krumholz HM. Predictors of cardiologist care for older patients hospitalized with heart failure. *Am Heart J* 2004; 147:66-73.
37. Hockensmith ML, Estacio RO, Mehler P, **Havranek EP**, Ecker ST, Lundgren RA, Schrier RW. Albuminuria is a predictor of heart failure in patients with type 2 diabetes. *J Cardiac Failure* 2004; 10: 126-131.
38. Steinberg J, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, **Havranek E**, Murray K, Olshansky B, O'Neil G, Sami M, Schmidt S, Storm R, Zabalgoita M, Miller J. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up

- Investigation of Rhythm Management (AFFIRM) Study. *Circulation* 2004; 109: 1973 – 1980.
39. Krantz MJ, **Havranek EP**, Mehler PS, Haynes DK, Long CS. Impact of a cardiac risk reduction program in vulnerable patients hospitalized with coronary artery disease. *Pharmacotherapy* 2004; 24: 768-775.
  40. **Havranek EP**, Wolfe P, Masoudi FA, Rathore SS, Krumholz HM, Ordin DL. The provider and hospital characteristics associated with geographic variation in the evaluation and management of elderly patients with heart failure. *Arch Int Med* 2004; 164: 1186-91.
  41. Masoudi FA, Rathore SR, Wang YF, **Havranek EP**, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. *Circulation* 2004; 110: 724-31.
  42. **Havranek EP**, Simon TA, L'Italien G, Smitten A, Hauber AB, Chen R, Lapuerta P. The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE sub-study. *J Cardiac Failure* 2004; 10: 339-43.
  43. Masoudi FA, Rumsfeld JS, **Havranek EP**, House JA, Peterson ED, Krumholz HM, Spertus JA. Age, functional capacity, and health-related quality of life in patients with heart failure. *J Cardiac Failure* 2004; 10: 368-73.
  44. **Havranek EP**, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS. Predictors of the onset of depressive symptoms in heart failure patients. *J Am Coll Cardiol* 2004; 44: 2333-8.
  45. Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, **Havranek EP**, Ordin DL, Krumholz HM. Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. *Am Heart J* 2005; 149: 121-8.
  46. Masoudi FA, Inzucchi SE, Wang Y, **Havranek EP**, Foody JM, Krumholz HK. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. *Circulation* 2005 111: 583 - 590.
  47. Hauptman PJ and **Havranek EP**. Integrating palliative care into heart failure care. *Arch Int Med* 2005; 165: 374-8.
  48. Smith GL, Shlipak MG, **Havranek EP**, Masoudi FA, McClellan WM, Foody JM, Rathore SS, Krumholz HM. Race and renal impairment in heart failure: mortality in blacks versus whites. *Circulation* 2005; 111: 1270-7.
  49. Krantz MJ, Zwang O, Rowan SB, Cleary B, Chu E, Reid MB, Cantrill SV, **Havranek EP**, Albert RK. A cooperative care model: cardiologists and hospitalists reduce length of stay in a chest pain observation unit. *Crit Pathways in Cardiol* 2005; 4: 55-58.
  50. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, **Havranek EP** and Krumholz HM. Insulin sensitizing anti-hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. *Diabetes Care*, 2005; 28:1680-9.
  51. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, **Havranek EP**, Krumholz HM. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. *Circulation* 2005; 111: 3078-86.

52. Masoudi FA, Gross CP, Wang Y, Rathore SS, **Havranek EP**, Foody JM, Krumholz HM. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. *Circulation* 2005;112:39-47.
53. Luther SA, McCullough PA, **Havranek EP**, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, Rathore SS, Krumholz HM, Weintraub WS, Spertus JA, Masoudi FA. The relationship between B-type natriuretic peptide and health status in patients with heart failure. *J Cardiac Failure* 2005; 11: 414-21.
54. Strickberger SA, Conti J, Daoud EG, **Havranek EP**, Mehra MR, Piña IL, Young J. Scientific advisory: patient selection for cardiac resynchronization therapy. *Circulation* 2005; 111: 2146-2150.
55. Masoudi FA, Pam Wolfe P, **Havranek EP**, Rathore SR, Foody JM, Krumholz HM. Aspirin use in older patients with heart failure and coronary artery disease: National prescription patterns and relationship with mortality. *J Am Coll Cardiol* 2005; 46: 955-962.
56. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JGF, **Havranek EP**, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW. ACC/AHA key data elements and data definitions for measuring the clinical management and outcomes of patients with heart failure: a report of the ACC/AHA Task Force on Clinical Data Standards (Heart Failure Data Standards Writing Committee). *J Am Coll Cardiol* 2005; 46: 1179 –207 and *Circulation* 2005; 112: 1888-1916.
57. Masoudi FA, Charles A. Baillie CA, Wang Y, Bradford WD, Steiner JF, **Havranek EP**, Foody JM, Krumholz HM. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. *Arch Intern Med* 2005; 165: 2069-2076.
58. Ko DT, Tu JV, Masoudi FA, Wang Y, **Havranek EP**, Rathore SS, Newman AM, Donovan LR, Lee DS, Foody JM, Krumholz HM. Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada *Arch Intern Med* 2005; 165: 2486-2492.
59. Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, **Havranek EP**, Krumholz HM. Anemia and outcomes in patients with heart failure: A study from the National Heart Care Project. *Arch Int Med*, in press.
60. Heidenreich PA, Spertus, JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, Peterson ED, Masoudi FA, Krumholz HM, **Havranek EP**, Conard MW, Williams RE. Health status identifies heart failure outpatients at risk for hospitalization or death. *J Am Coll of Cardiol*, in press.

Books, Chapters, Editorials, Secondary Publications, Letters to the Editor

1. **Havranek EP**. Ethics of patient-sponsored research. *N Engl J Med* 1987;317:172.
2. **Havranek EP**. Lipid levels and affluent diets. *N Engl J Med* 1992;327:53.
3. **Havranek EP** and Adair OV. "Ischemic heart disease", in *Emergency Medicine Secrets*, Hanley and Belfus, Philadelphia, 1993.
4. Adair OV and **Havranek EP**, eds, *Cardiology Secrets*, Hanley and Belfus, Philadelphia, 1994.

- **Havranek EP.** Bedside hemodynamic monitoring. Chapter 4 *ibid.*
  - **Havranek EP.** Congestive heart failure. Chapter 21. *ibid.*
  - **Havranek EP.** Traumatic heart disease. Chapter 31. *ibid.*
  - **Havranek EP.** Aortic stenosis and regurgitation. Ch. 43. *ibid.*
5. Myers AM and **Havranek EP.** Myocardial infarction occurring three years after mantle irradiation in a 32 year old woman with severe hypercholesterolemia. *Am J Hematol*, 1998;57:180-81.
  6. **Havranek EP.** The effects of the angiotensin II receptor antagonist irbesartan in patients with CHF. *Cardiovascular Reviews and Reports* 1998;19:29-33.
  7. **Havranek EP** and Abraham WT. The health care economics of heart failure. *Heart Failure* 1998; 14:10-18.
  8. **Havranek EP.** "Ischemic heart disease", in *Emergency Medicine Secrets*, 2d ed. Hanley and Belfus, Philadelphia, 1999.
  9. **Havranek EP**, Stevens E, Parker K, Abrams F. Mortality in elderly patients with heart failure. *Cardiology Reviews* 1999; 16: 40-5.
  10. **Havranek EP** and Weinberger J. Update on the treatment of heart failure. *Prog Cardiovasc Nursing* 1999; 15: 111-3.
  11. **Havranek EP.** Commentary on Rubins et al, "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol". *ACP Journal Club* 2000; 132: 44.
  12. **Havranek EP.** Commentary on Pitt et al, "Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II". *ACP Journal Club* 2000; 133: 87.
  13. **Havranek EP** (series editor). Improving heart failure care: HCFA's initiative.
    - Ordin DL, Masoudi FA, Krumholz HM, **Havranek EP.** Medicare initiatives to improve heart failure care: An introduction. *CHF* 2000; 6: 280-2.
    - Masoudi FA, Ordin DL, Delaney RJ, Krumholz HM, **Havranek EP.** The National Heart Failure Project: A Health Care Financing Administration initiative to improve the care of Medicare beneficiaries with heart failure. *CHF* 2000; 6: 377-9.
    - Masoudi FA, Ralston DL, Wolfe P, **Havranek EP**, Shah VP, Krumholz HM, Ordin DL. Baseline quality indicator rates from the Nation Heart Failure Project: A HCFA initiative to improve the care of Medicare Beneficiaries with heart failure. *CHF* 2001; 7: 53-6.
    - Taylor J, Mulgrew C, Hayes R, Ordin DL, **Havranek EP.** Heart failure practice improvement effort in the outpatient setting: a Health Care Financing Administration initiative to improve the care of Medicare beneficiaries with heart failure. *CHF* 2001; 7: 105-8.
    - Delaney R, **Havranek EP**, Ordin DL, Taylor J. Profiles of quality improvement efforts in heart failure care. *CHF* 2001; 7: 166-9.
    - **Havranek EP**, Masoudi FA, Smith G, Wolfe P, Ralston DL, Krumholz HM, Ordin DL. Lessons learned from the National Heart Failure project. *CHF* 2001; 7: 334-6.
    - Ramunno LD, French LL, Ligor ML, **Havranek EP**, Taylor JP, Ordin DL. Improving heart failure care in outpatient practices. *CHF* 2002; 8 : 86-89.

- **Havranek EP**, Masoudi FA, Ralston DL, Krumholz HM, Taylor JP. Future challenges in quality improvement in heart failure. CHF, in press.
- 14. **Havranek EP**. Commentary on Pignone et al, "Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials" ACP Journal Club 2000; 134: 92.
- 15. **Havranek EP**. Editorial Comment- Catching the missed opportunities in heart failure. J Cardiac Failure 2001; 7: 239-40.
- 16. Masoudi FM and **Havranek EP**. Race and responsiveness to drugs for heart failure. N Engl J Med 2001; 345: 767.
- 17. **Havranek EP**. Book Review: Lactate Threshold Training. Am J Med Sports 2002; 4:407.
- 18. **Havranek EP**. Commentary on Page et al, "Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial" ACP Journal Club 2003; 138: 8.
- 19. **Havranek EP**. Book Review: Performing in Extreme Environments. Am J Med Sports 2003; 5:111.
- 20. **Havranek EP**. Commentary on Shepherd et al, "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial " ACP Journal Club 2003; 139:9 and Evidence-based Medicine 2003; 8:107.
- 21. Foody JM, Ferdinand FD, Galusha D, Rathore SS, Masoudi FA, **Havranek EP**, Nilasena D, Radford MJ, Krumholz HM. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 2003; 108; II-24 – II-28.
- 22. **Havranek EP** and Masoudi FA. Editorial Comment- What we're talking about when we talk about race. J Am Coll Cardiol 2004; 43: 436-7.
- 23. **Havranek EP**. Commentary on Mora et al, "Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the Lipid Research Clinics Prevalence Study" ACP Journal Club 2004; 140: 79.
- 24. **Havranek EP** and Steiner JF. Editorial- Valuation of health states in the US versus the UK: Two measures divided by a common language? Med Care 2005; 43: 201-2.
- 25. **Havranek EP**. Editorial Comment- Improving the outcomes of heart failure care: putting technology second. J Am Coll Cardiol 2005; 45:1665-6.
- 26. Nallamotheu B, **Havranek EP**, Masoudi FM, Casscells WS, Payvar S, Foody JM, Kosiborod MH, Wang Y, Krumholz HM. Research Correspondence- Admission body temperature and mortality in elderly patients hospitalized for heart failure. J Am Coll Cardiol. in press.

---

**Funded Research**

---

1. Latinos Using Cardiovascular Health Actions to Reduce Risk. NHLBI 1 U01 HL079160  
<http://clinicaltrials.gov/show/NCT00101530>  
Principal Investigator  
2004 - 2009  
\$2,985,310
  
2. Interactive Voice Recognition Technology for the Management of Hypertension. CO Dept  
of Public Health  
Co-Investigator  
2006-2008  
\$1,146,826